Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

Sionna Therapeutics is well-positioned for success, with a clear focus on developing innovative therapies for cystic fibrosis. Their strong financial position and strategic plans for future research and development demonstrate their commitment to delivering meaningful benefits to CF patients. Clinical trials have shown promising results and the company's focus on complementary treatments and potential combination therapies further solidify their potential for growth and success in the biotech industry.

Bears say

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis (CF) patients by targeting the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein. Their current phase 2a study, which is set to read out this summer, is utilizing their proprietary NBD1 modulator, SION-719, in combination with Trikafta, in order to demonstrate efficacy and de-risk their other NBD1 corrector, SION-451. However, there are several risks to the investment thesis and valuation, including pipeline risk, clinical risk, competitive risk, commercial risk, and financial risk. While the company has a promising platform and potential commercial opportunity, there are uncertainties surrounding the success of their clinical studies and the ability to gain significant market share in a competitive landscape dominated by Vertex Pharmaceuticals.

SION has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 10 analysts, SION has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.